CG Oncology, Inc. to unveil new data on CORE-008 Cohort CX for bladder cancer

CG Oncology, Inc. to unveil new data on CORE-008 Cohort CX for bladder cancer
CG Oncology, Inc. unveils bladder cancer data

CG Oncology, Inc. has announced its planned participation at the upcoming American Urological Association Annual Meeting, where it will present initial results from its CORE-008 Cohort CX study in bladder cancer.

This marks an important milestone for the company as it aims to advance research in bladder cancer treatment. CG Oncology, Inc. invited attendees to review these findings at #AUA26, aligning with its commitment to introducing new data to the urological community.

CG Oncology, Inc. has recently focused on addressing the persistent risk of bladder cancer recurrence despite approved NMIBC therapies, according to a previous update. The company also reported its first quarter 2026 financial results alongside new urology business developments earlier this year in a separate announcement. These initiatives reflect an ongoing emphasis on research and development within the bladder cancer space.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.